3T Biosciences secures $40 million in Series A financing
3T Biosciences is an immunotherapy developer with the 3T-TRACE platform, which combines a highly diverse target library with AI machine learning technology to identify novel targets and TCRs. This platform can identify tumor-specific anti-tumor immune responses from patient samples and discover the most prevalent and immunogenic targets in solid tumors. 3T Biosciences announced that it […]
3T Biosciences secures $40 million in Series A financing Read More »